



Sa Sa Appoints Mr David Chung as Chief Financial Officer

(13 December 2024 - HONG KONG) - Sa Sa International Holdings Limited (“Sa Sa” or the “Group”, stock code: 0178) is pleased to announce the appointment of Mr David Chung as Chief Financial Officer, effective 2 December 2024, succeeding Mr Danny Ho. Mr Ho has resigned as executive director, chief financial officer, member of the executive committee, member of the risk management committee and authorised representative of the Company with effect from 13 December 2024 to pursue other opportunities. The Board further announces that Ms Melody Kwok has been appointed as the authorised representative of the Company with effect from 13 December 2024.

Mr Chung has over 20 years of experience in finance, accounting and management. Prior to joining Sa Sa, Mr Chung had worked in an international accounting firm and other companies listed on the Main Board of the Stock Exchange of Hong Kong, NASDAQ and the Singapore Exchange. Mr Chung obtained his Bachelor’s degree of business administration in accounting from the Hong Kong University of Science and Technology. He is a Chartered Financial Analyst of the CFA Institute and a fellow member of the Hong Kong Institute of Certified Public Accountants. He is also an independent non-executive director of Cutia Therapeutics, a company whose shares are listed on the Stock Exchange of Hong Kong, since 12 June 2023.

Dr Simon Kwok, SBS, JP, Chairman and Chief Executive Officer of the Group, said, “We welcome Mr Chung to our team. Mr Chung brings a wealth of experience and a proven track record of success in financial leadership. With deep industry knowledge and expertise in strategic planning, I believe Mr Chung will contribute greatly to the continued success and sustainable development of Sa Sa. We also want to express our gratitude to Mr Ho for his contributions to the Company during his tenure of service. We wish him all the best in his future endeavours.”

– END –